Cargando…

CX-4945 and siRNA-Mediated Knockdown of CK2 Improves Cisplatin Response in HPV(+) and HPV(−) HNSCC Cell Lines

Head and neck squamous cell carcinoma (HNSCC) can be categorized into human papillomavirus (HPV) positive or negative disease. Elevated protein kinase CK2 level and activity have been historically observed in HNSCC cells. Previous studies on CK2 in HNSCC did not generally include consideration of HP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trembley, Janeen H., Li, Bin, Kren, Betsy T., Gravely, Amy A., Caicedo-Granados, Emiro, Klein, Mark A., Ahmed, Khalil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158385/ https://www.ncbi.nlm.nih.gov/pubmed/34070147 http://dx.doi.org/10.3390/biomedicines9050571

Ejemplares similares

Identification of high protein kinase CK2α in HPV(+) oropharyngeal squamous cell carcinoma and correlation with clinical outcomes
por: Trembley, Janeen H., et al.
Publicado: (2021)

Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells
por: Zanin, Sofia, et al.
Publicado: (2012)

Protein kinase CK2 – diverse roles in cancer cell biology and therapeutic promise
por: Trembley, Janeen H., et al.
Publicado: (2022)

CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism
por: Lertsuwan, Jomnarong, et al.
Publicado: (2018)

Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945
por: Rosales, Mauro, et al.
Publicado: (2021)

Structural Determinants of CX-4945 Derivatives as Protein Kinase CK2 Inhibitors: A Computational Study
por: Liu, Hongbo, et al.
Publicado: (2011)

Different Persistence of the Cellular Effects Promoted by Protein Kinase CK2 Inhibitors CX-4945 and TDB
por: Girardi, Cristina, et al.
Publicado: (2015)

Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia
por: Klink, Morgann, et al.
Publicado: (2021)

Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy – potential clinical relevance
por: D’Amore, Claudio, et al.
Publicado: (2020)

CK2 Molecular Targeting—Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer
por: Trembley, Janeen H., et al.
Publicado: (2017)

CX-4945: the protein kinase CK2 inhibitor and anti-cancer drug shows anti-fungal activity
por: Masłyk, Maciej, et al.
Publicado: (2017)

Validation of an LC–MS/MS Method for the Quantification of the CK2 Inhibitor Silmitasertib (CX-4945) in Human Plasma
por: Schwarz, Rico, et al.
Publicado: (2022)

CK2 Pro-Survival Role in Prostate Cancer Is Mediated via Maintenance and Promotion of Androgen Receptor and NFκB p65 Expression
por: Trembley, Janeen H., et al.
Publicado: (2019)

Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice
por: Ferrer-Font, Laura, et al.
Publicado: (2017)

Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines
por: Busch, Chia-Jung, et al.
Publicado: (2016)

The Impact of YRNAs on HNSCC and HPV Infection
por: Guglas, Kacper, et al.
Publicado: (2023)

Identification of a Novel Function of CX-4945 as a Splicing Regulator
por: Kim, Hyeongki, et al.
Publicado: (2014)

MEK Inhibitor PD-0325901 Overcomes Resistance to CK2 Inhibitor CX-4945 and Exhibits Anti-Tumor Activity in Head and Neck Cancer
por: Bian, Yansong, et al.
Publicado: (2015)

CK2 Inhibitor CX-4945 Blocks TGF-β1-Induced Epithelial-to-Mesenchymal Transition in A549 Human Lung Adenocarcinoma Cells
por: Kim, Jiyeon, et al.
Publicado: (2013)

Tenfibgen Ligand Nanoencapsulation Delivers Bi-Functional Anti-CK2 RNAi Oligomer to Key Sites for Prostate Cancer Targeting Using Human Xenograft Tumors in Mice
por: Trembley, Janeen H., et al.
Publicado: (2014)

Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945
por: Lee, Joo Youn, et al.
Publicado: (2019)

Correction: Lertsuwan et al. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. Cancers 2018, 10, 283
por: Lertsuwan, Jomnarong, et al.
Publicado: (2022)

Roscovitine strongly enhances the effect of olaparib on radiosensitivity for HPV neg. but not for HPV pos. HNSCC cell lines
por: Ziemann, Frank, et al.
Publicado: (2017)

Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective
por: Grygier, Przemyslaw, et al.
Publicado: (2023)

4,5,7‐Trisubstituted indeno[1,2‐b]indole inhibits CK2 activity in tumor cells equivalent to CX‐4945 and shows strong anti‐migratory effects
por: Birus, Robin, et al.
Publicado: (2021)

Cyclin A1 shows age-related expression in benign tonsils, HPV16-dependent overexpression in HNSCC and predicts lower recurrence rate in HNSCC independently of HPV16
por: Weiss, Daniel, et al.
Publicado: (2012)

The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies
por: Chon, Hae J., et al.
Publicado: (2015)

CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors
por: Ahmed, Khalil, et al.
Publicado: (2016)

HPV-16 infection modifies overall survival of Puerto Rican HNSCC patients
por: Rivera-Peña, Bianca, et al.
Publicado: (2016)

mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC
por: Coppock, Joseph D., et al.
Publicado: (2016)

Expressed HNSCC variants by HPV-status in a well-characterized Michigan cohort
por: Qin, Tingting, et al.
Publicado: (2018)

HPV impacts survival of stage IVC non-oropharyngeal HNSCC cancer patients
por: Burr, Adam R, et al.
Publicado: (2018)

CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC
por: Paulsen, Finn-Ole, et al.
Publicado: (2020)

GA-OH enhances the cytotoxicity of photon and proton radiation in HPV(+) HNSCC cells
por: Chitsike, Lennox, et al.
Publicado: (2023)

Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma()()()
por: Zakharia, Kais, et al.
Publicado: (2018)

Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy
por: Kren, Betsy T, et al.
Publicado: (2015)

CDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma Cells
por: Ahmed, Rehana L., et al.
Publicado: (2019)

Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB
por: Buontempo, Francesca, et al.
Publicado: (2015)

FcGBP was upregulated by HPV infection and correlated to longer survival time of HNSCC patients
por: Wang, Yating, et al.
Publicado: (2017)

Enhancer RNA Profiling in Smoking and HPV Associated HNSCC Reveals Associations to Key Oncogenes
por: Shende, Neil, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_va499bf7n4q9ngo6mmfd78lk72